Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Strata Critical Medical's revenue for the
three
months ended in Mar. 2026 was $67.4 Mil.
Its revenue for the trailing twelve months (TTM) ended in Mar. 2026 was $254.3 Mil.
Strata Critical Medical's Revenue per Share for the
three
months ended in Mar. 2026 was $0.75.
Its Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $3.01.
During the past 7 years, Strata Critical Medical's highest 3-Year average Revenue per Share Growth Rate was 48.80% per year. The lowest was 5.40% per year. And the median was 17.85% per year.
Strata Critical Medical (NAS:SRTA) Revenue Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Care Facilities subindustry, Strata Critical Medical's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Strata Critical Medical Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Strata Critical Medical's Revenue distribution charts can be found below:
* The bar in red indicates where Strata Critical Medical's Revenue falls into.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $254.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Strata Critical Medical (SRTA) has a Revenue of $254.3 Mil as of Mar. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Strata Critical Medical and its competitors.
Is Strata Critical Medical's Revenue too high?
Strata Critical Medical's current Revenue is $254.3 Mil. Overall, Strata Critical Medical has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Strata Critical Medical's Revenue compare to CYH and CCRN?
Strata Critical Medical's Revenue of $254.3 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Healthcare Providers & Services company?
A good Revenue depends on the Healthcare Providers & Services industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Strata Critical Medical and its competitors. Strata Critical Medical's current Revenue is $254.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Strata Critical Medical stock overvalued right now?
Based on GuruFocus' analysis, Strata Critical Medical (SRTA) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.48, compared to a current price of $5.06 — trading 12.9% above its estimated fair value. The current Revenue is $254.3 Mil. Strata Critical Medical's overall GF Score™ is 68/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Strata Critical Medical (SRTA), the current Revenue is $254.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Strata Critical Medical (SRTA) Overvalued in 2026?
Based on GuruFocus' analysis, Strata Critical Medical stock appears to be overvalued.
The current stock price of $5.06 is trading 12.9% above its estimated GF Value™ of $4.48.
GuruFocus considers Strata Critical Medical to be Modestly Overvalued.
Key valuation signals for SRTA:
Revenue: $254.3 Mil
GF Value™: $4.48 vs. price of $5.06 (12.9% above fair value)
No single metric tells the full story. See the SRTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
68GF Score
Get the complete analysis for SRTA
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRTA has been successfully added to your 
